Dale L Ludwig

Dale L Ludwig

UNVERIFIED PROFILE

Are you Dale L Ludwig?   Register this Author

Register author
Dale L Ludwig

Dale L Ludwig

Publications by authors named "Dale L Ludwig"

Are you Dale L Ludwig?   Register this Author

43Publications

1234Reads

30Profile Views

Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance--implications for IGF-II and IGF-IR-targeted therapy.

Clin Cancer Res 2014 May 5;20(10):2651-62. Epub 2014 Mar 5.

Authors' Affiliations: Department of Anatomy, Centre for Cancer Research; Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR; Institute of Life and Health Engineering, Jinan University, Guangzhou, China; and ImClone Systems Corporation, a wholly owned subsidiary of Eli Lilly & Co, New York, New YorkAuthors' Affiliations: Department of Anatomy, Centre for Cancer Research; Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR; Institute of Life and Health Engineering, Jinan University, Guangzhou, China; and ImClone Systems Corporation, a wholly owned subsidiary of Eli Lilly & Co, New York, New York

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/20/10/2651.ful
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-2735DOI Listing
May 2014

Development of a novel and efficient cell culture flocculation process using a stimulus responsive polymer to streamline antibody purification processes.

Biotechnol Bioeng 2013 Nov 29;110(11):2928-37. Epub 2013 Jun 29.

Bioprocess Sciences, ImClone Systems, a Wholly-Owned Subsidiary of Eli Lilly and Company, 450 East 29th Street, New York, New York, 10016.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/bit.24969DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812681PMC
November 2013

A universal combinatorial design of antibody framework to graft distinct CDR sequences: a bioinformatics approach.

Proteins 2012 Mar 16;80(3):896-912. Epub 2011 Dec 16.

Department of Antibody Technology, ImClone Systems, a Wholly-Owned Subsidiary of Eli Lilly and Company, Alexandria Center for Life Sciences, New York, New York 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/prot.23246DOI Listing
March 2012

Blockade of insulin-like growth factor type-1 receptor with cixutumumab (IMC-A12): a novel approach to treatment for multiple cancers.

Curr Drug Targets 2011 Dec;12(14):2016-33

Department of Clinical Research and Regulatory Affairs, ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, Bridgewater, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138945011798829401DOI Listing
December 2011

Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells.

Eur J Cancer 2011 Jul 28;47(11):1717-26. Epub 2011 Mar 28.

Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2011.02.019DOI Listing
July 2011

Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.

Proc Natl Acad Sci U S A 2010 Jun 10;107(24):10791-8. Epub 2010 May 10.

Department of Biochemistry and Biophysics, Diabetes Center, University of California, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0914076107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890766PMC
June 2010

Transforming Growth Factor-{beta}-Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition.

Clin Cancer Res 2009 Dec;15(24):7634-7641

Authors' Affiliations: Departments of Medicine and Urology, University of Washington; Puget Sound Veterans Affairs Health Care System; Fred Hutchinson Cancer Research Center, Seattle, Washington and Imclone Systems, Inc., New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-0264DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795132PMC
December 2009

Insulin-like growth factor type 1 receptor and insulin receptor isoform expression and signaling in mammary epithelial cells.

Endocrinology 2009 Aug 30;150(8):3611-9. Epub 2009 Apr 30.

Department of Neurology and Neuroscience, University Hospital Cancer Center, New Jersey Medical School/University of Medicine and Dentistry of New Jersey, Newark, New Jersey 07101, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/en.2008-1473DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2717875PMC
August 2009

Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.

Anticancer Res 2009 Jun;29(6):1999-2007

ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, New York, NY10014, U.S.A.

View Article

Download full-text PDF

Source
June 2009

Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.

Lung Cancer 2008 May 14;60(2):166-74. Epub 2007 Nov 14.

Department of Medicine, Virginia Commonwealth University, Richmond, VA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2007.09.023DOI Listing
May 2008

Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1.

Hum Antibodies 2007 ;16(3-4):127-36

ImClone Systems Incorporated, 180 Varick Street, New York, NY 10014, USA.

View Article

Download full-text PDF

Source
April 2008

IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.

Clin Cancer Res 2007 Sep;13(18 Pt 2):5549s-5555s

Department of Clinical Research and Regulatory Affairs, ImClone Systems Incorporated, Branchburg, New Jersey 08876, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-1109DOI Listing
September 2007

Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis.

Cancer Immunol Immunother 2007 Mar 11;56(3):343-57. Epub 2006 Jul 11.

James Ewing Laboratory of Developmental Hematopoiesis, Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-006-0196-9DOI Listing
March 2007

Insulin-like growth factor-I receptor signaling blockade combined with radiation.

Cancer Res 2007 Feb;67(3):1155-62

Department of Human Oncology, School of Medicine and Comprehensive Cancer Center, University of Wisconsin Hospital and Clinics, 600 Highland Avenue, Madison, WI 53792, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-06-2000DOI Listing
February 2007

Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies.

J Immunol Methods 2007 Jan 26;318(1-2):65-74. Epub 2006 Oct 26.

Department of Antibody Technology, Department of Cell Engineering and Expression, ImClone Systems Incorporation, 180 Varick Street, New York, NY 10014, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jim.2006.09.020DOI Listing
January 2007

Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.

Biochem Biophys Res Commun 2006 Jun 2;345(1):438-45. Epub 2006 May 2.

Departments of Antibody Technology, Protein Science, and Cell Engineering and Expression, ImClone Systems Incorporated, New York, NY 10014, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2006.04.119DOI Listing
June 2006

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

Cancer Res 2006 Feb;66(3):1500-8

Program in Molecular Pharmacy and Chemistry, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-05-2925DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3193604PMC
February 2006

Monoclonal antibody therapeutics and apoptosis.

Oncogene 2003 Dec;22(56):9097-106

ImClone Systems Incorporated, 180 Varick Street, New York, NY 10014, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/1207104
Publisher Site
http://dx.doi.org/10.1038/sj.onc.1207104DOI Listing
December 2003